Search the Newsreel

Earnings Release: Here's Why Analysts Cut Their Pacific Biosciences of California, Inc. (NASDAQ:PACB) Price Target To US$2.29

Analysts have lowered their price target for Pacific Biosciences of California (NASDAQ:PACB) to US$2.29 after the company's recent earnings report, which saw revenue fall short of estimates and increased projected losses per share for 2026. The revised forecasts indicate a slowdown in revenue growth …

Pacific Biosciences of California (NASDAQ:PACB) Cut to "Sell" at Wall Street Zen

Wall Street Zen has downgraded Pacific Biosciences of California (NASDAQ:PACB) from a "hold" to a "sell" rating. The company recently missed its quarterly earnings and revenue estimates, reporting a loss of $0.14 per share and $39.01 million in revenue. Analysts currently hold a "Reduce" …

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 2026: Revenue $39.01M, EPS ($0.14) — 10-Q Summary

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) reported its current quarter 2026 results, showing largely flat revenue year-over-year at $39.01M and a net loss that widened to ($44.74M), though diluted EPS remained ($0.14). The company is focusing on shifting towards clinical and commercial accounts, increasing …

Pacific Biosciences of California, Inc. Stock 12‑Month Price Target Cut to $2.29, Implies 76% Upside

The average 12-month price target for Pacific Biosciences of California, Inc. (PACB) stock has been lowered from $2.46 to $2.29 by 6 analysts, suggesting a potential upside of approximately 76% from its August 5th closing price. Despite the target cut, the consensus rating from …

TD Cowen Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Maintains Target Price $3

TD Cowen has reiterated its Buy rating on Pacific Biosciences of California (PACB.US) and maintained its target price at $3. This indicates a continued positive outlook from the firm regarding the company's stock performance.

Pacific Biosciences of California Q2 Earnings Call Highlights

Pacific Biosciences of California (PACB) reported Q2 2026 revenue of $39 million, largely flat year-over-year, and announced a leadership change with Mark Van Oene succeeding Christian Henry as CEO. The company lowered its full-year revenue outlook due to slower rollout of new sequencing chemistry …

ETFs Investing in Pacific Biosciences of California, Inc. Stocks

This article lists various ETFs that include Pacific Biosciences of California, Inc. (PACB) stocks in their holdings. It provides a detailed table for each ETF, including market value, weight, issuer, management style, focus, expense ratio, assets under management (AUM), price, change percentage, relative volume, …

Pacific Biosciences: It's Only Getting Worse (NASDAQ:PACB)

Pacific Biosciences reported disappointing Q2 revenues of $39.01 million, missing estimates and lowering its 2026 revenue guidance below consensus. The company continues to face sizable operating and net losses, with cash reserves dwindling and significant debt outstanding. Despite trading at a steep discount to …

PacBio forecasts $155M-$165M 2026 revenue while shifting to a leaner structure and pushing SPRQ-Nx adoption

Earnings Call Insights: Pacific Biosciences of California (PACB) Q2 2026 MANAGEMENT VIEW * "Earlier today, we announced that I am stepping down as President and Chief Executive Officer of PacBio and that Mark Van Oene will lead the company as President and Chief Executive …

PacBio Q2 2026 slides: SPRQ-Nx launch amid revenue miss, cut guidance

Pacific Biosciences (NASDAQ:PACB) reported a mixed Q2 2026, launching its SPRQ-Nx sequencing chemistry but missing revenue expectations and lowering full-year guidance. The company's stock declined following the announcement, as it also delayed its cash flow breakeven target to 2028. Despite clinical validation of its …

PacBio Announces Faster Runs, Up to 50% More HiFi Data, and New Compliance Controls for the Vega system

MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, today announced the upcoming availability of SPRQ-Nx chemistry and an accompanying software update for its Vega systems. Together, the updates expand the range of …

Pacific Biosciences of California (PACB) Reports Q2 Loss, Lags Revenue Estimates

PACB5949325 Bond Profile — Key Metrics

This article provides a detailed profile of the PACB5949325 bond issued by Pacific Biosciences of California, Inc. Key metrics include a 1.5% coupon rate, an issue date of November 21, 2024, and a maturity date of August 15, 2029. The bond has an outstanding …

PACB5949325 Bond Risk Profile

This page provides a risk profile for the PACB5949325 bond issued by Pacific Biosciences of California, Inc. It details the bond's coupon, redemption information, and a credit risk assessment section, including security level and issuer rating. The platform also offers access to analyst ratings …

Pacific Biosciences of California Inc (PACB) Financial Health: Profitability & Balance Sheet Analysis

This article provides a financial health analysis of Pacific Biosciences of California Inc (PACB), noting its current financial score of 5.83, which ranks it low within the Healthcare Equipment & Supplies industry. Despite its weak financial status and low operating efficiency, the company reported …

Pacific Biosciences of California Inc (PACB) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Pacific Biosciences of California Inc (PACB), detailing its volatility, financial risk, and investment risk. The company's risk assessment score is 3.44, ranking it 120 out of 199 in the Healthcare Equipment & Supplies industry. Key metrics such …

PACB5630687 Bond Profile — Key Metrics

This article provides a detailed profile of the PACB5630687 bond issued by Pacific Biosciences of California, Inc. Key metrics include its 1.375% coupon, maturity date of December 15, 2030, and an outstanding amount of $441 million. The company, founded in 2000, specializes in advanced …

Pacific Biosciences of California (PACB) Laps the Stock Market: Here's Why

Pacific Biosciences of California (PACB) closed up 2.21% in its latest trading session, outperforming the S&P 500. The company is set to release its earnings on August 5, 2026, with an expected year-over-year decline in EPS but a rise in revenue. Analysts' estimate revisions …

PacBio to Participate in the Canaccord Genuity 46th Annual Growth Conference

PacBio (NASDAQ: PACB) announced its participation in the upcoming Canaccord Genuity 46th Annual Growth Conference. Christian Henry, President and Chief Executive Officer, is scheduled to present on Wednesday, August 14, 2024, at 9:00 AM ET. A live audio webcast will be available for those …

PacBio Management Chat Set for Aug. 11 With Live Webcast

PacBio (NASDAQ: PACB) announced that its management will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 11, 2026, at 9:00 AM ET in Boston, Massachusetts. A live webcast and replay will be available on the company’s investor …

Pacific Biosciences of California Inc (PACB) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Pacific Biosciences of California Inc (PACB), listing major individual and institutional holders. It provides a breakdown of shareholder types, institutional shareholding over time from Q4 2023 to Q1 2026, and a list of related ETFs that hold …

Pacific Biosciences of California Inc (PACB) Institutional Confidence

This article analyzes the institutional confidence score for Pacific Biosciences of California Inc (PACB), which stands at 5.00, placing it 107th in the Healthcare Equipment & Supplies industry. Institutional shareholding proportion increased by 10.93% quarter-over-quarter to 62.12%. Catherine Wood is the largest institutional shareholder …

Pacific Biosciences of California, Inc. Revenue Breakdown – NASDAQ:PACB

Pacific Biosciences of California, Inc. (NASDAQ: PACB) generated a total revenue of $160.00 million USD last year. The "Consumable" segment was the top-performing segment, contributing $81.94 million USD, an increase from $70.37 million USD in the previous year. Geographically, the United States was the …

Pacific Biosciences of California Inc

This article provides a detailed revenue breakdown for Pacific Biosciences of California Inc (PACB), categorized by business segments and geographical regions. As of April 6, the company's revenue is primarily driven by consumable sales (51.21%), followed by instrument sales (33.64%) and service/other revenue (15.15%). …

PACB Cash Flow Statement

This article presents the quarterly and annual cash flow statements for Pacific Biosciences of California Inc (PACB), detailing operating, investing, and financing cash flows from FY2012Q1 to FY2026Q1. It provides a comprehensive breakdown of various cash flow components, including net income, operating gains/losses, deferred …

PACB|Pacific Biosciences of California Inc|Price:1.360|Chg%:-0.040

This article provides an overview of Pacific Biosciences of California Inc (PACB), a life science technology company specializing in advanced sequencing solutions. It details the company's products, technologies like HiFi long-read sequencing, and applications in various scientific fields. The article also lists company information, …

Pacific Biosciences of California Inc (PACB) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Pacific Biosciences of California Inc (PACB) dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past five years, indicating no recent dividend payouts. The page also presents current stock performance …

Here's Why Pacific Biosciences of California (PACB) Fell More Than Broader Market

PacBio to Report Second Quarter 2026 Financial Results on August 5, 2026

PacBio (NASDAQ: PACB) announced it will report its second-quarter 2026 financial results on Wednesday, August 5, 2026, at 4:30 p.m. Eastern Time. The company will host a conference call and webcast, accessible via its investor relations website, to discuss these results. PacBio is a …

PacBio’s next earnings update will stream live Aug. 5

PacBio (NASDAQ: PACB) announced that it will host a quarterly conference call on Wednesday, August 5, 2026, at 4:30 p.m. Eastern Time, to discuss its second quarter 2026 financial results. Investors can access the live webcast or replay via PacBio's investor relations website or …

Pacific Biosciences of California (PACB) Dips More Than Broader Market: What You Should Know

Pacific Biosciences of California (PACB) Stock Drops Despite Market Gains: Important Facts to Note

Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: Here's Why